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Abstract
Stress is known to exert an influence on neuroendocrine, autonomic, hormonal, and
immune functioning. As a result of the debilitating effects of stress on numerous bodily
systems, there exists a large body of research devoted to the etiology, physiological
sequelae, and treatment of the condition. Further, the neurotransmitter serotonin (5-HT)
has been implicated in stress responding. Presently, there is conflict in the literature as to
the precise role serotonin plays in mediating the stress response. This study was an
attempt to further elucidate the role of 5-HT in mediating an organism’s response to tail
pinch stress and the open field. Previously, we have demonstrated that peripheral
administration of the broad-spectrum 5-HT2 agonist, DOI, reduces stress responding in
rats subjected to a tail pinch stressor (Hawkins, et al., 2002). This effect was fully
blocked by peripheral coadministration of the broad spectrum 5-HT2 antagonist,
ketanserin. The present study examined further the role of the 5-HT2 receptor subclass in
mediating the stress response. We employed antagonists that selectively target either the
5-HT2A or 5-HT2C receptor in an effort to clarify the relative importance of each of
these receptors in mediating the stress response. These compounds were injected
subcutaneously in an effort to black the effects previously seen with DOI. DOI
attenuated rearing and oral behavior directed at food, while increasing the frequency of
head and body shakes in the open field. DOI-induced head shakes were blacked by the
5-HT2C antagonist, SDZ SER 082, as well as by a combination of SDZ SER 082 and the
5-HT2A antagonist, spiperone. Implications for the 5-HT2 receptor subclass in mediating
stress responding are discussed.
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Introduction
Stress can be described as an organism’s response to any influence exerted by
environmental or endogenous factors that disrupt homeostatic mechanisms within the
organism. These influences, or stressors, can be physical or psychological in nature, and
have wide-ranging effects on neuroendocrine, autonomic, immune, and hormonal function.
In humans, stress has been linked to a broad spectrum of illnesses, including major depressive
disorders, Alzheimer’s disease, general neurodegeneration, hypertension, and asthma
(McEwen and Stellar, 1993). Given the well-known debilitating effects of stress, there exists
a large body of literature aimed at elucidating the etiology, physiological sequelae, and
treatment of the condition.
General Theories of Stress
In Walter Cannon’s classic “fight-or-flight” paradigm, an organism’s sympathetic
nervous system is activated in response to physical and emotional stressors. In the case of a
physical threat, the “fight or flight” reaction is a near-instantaneous sympathetic response that
allows an organism to engage, or escape from a perceived environmental threat, such as a
natural predator. Cannon noted that milder emotional states such as joy, grief, or disgust
were capable of prompting sympathetic arousal as well (Cannon, 1929). Despite categorical
distinctions, physical and emotional stressors were thought to prompt similar, if not equal
activation of the sympathetic nervous system. Additionally, Cannon coined the term
homeostasis in reference to an organism’s ability to maintain internal constancy in the face of
great changes in the surrounding environment.
Building upon the work of Cannon, Austrian physician-endocrinologist Hans Selye
created a theoretical model aimed at describing an organism’s nonspecific responses to

1

stress. Observing several common features of “sickness” in patients diagnosed with a
wide range of illnesses, Selye developed a model termed the General Adaptation
Syndrome (GAS), which outlined the physiological processes associated with the stress
response (Selye, 1956). The GAS offered no theoretical distinctions between the body’s
response to emotional or physiological factors, be they positive or negative. Selye argued
that the body responded in a nonspecific manner, via the GAS, to an essentially infinite
amount of specific stressors (Selye, 1956). Perhaps most notably, Selye theorized that
neuroendocrine responses to stress were intrinsically related to immune functioning. As
such, many ailments resulted not from a specific influence, such as intoxication or
infection, but from the inability of an organism to respond appropriately to the stressor
through activation of the GAS. Thus, when an organism failed to meet the demands
placed upon it by stress, certain physiological manifestations such as ulceration and
hypertension would surface.
The theories of Cannon and Selye provide groundwork for understanding the
physiological responses associated with stress, particularly with regard to nonspecific
sympathetic arousal, which will be discussed later. In contrast, the recent work of James
Deakin and Frederico Graeff has culminated in a theoretical model that distinguishes
between various types of stressors, while proposing distinct neural mechanisms
associated with each of them (Graeff, Guimares, Andrades, and Deakin, 1996). This
particular theory hinges largely on an organism’s response to proximal and distal threats
(Graeff, et al., 1996). Potential (distal) threats are theorized to activate neural substrates
that mediate anticipatory anxiety in situations where an organism must evaluate a
possible threat. Conversely, proximal threats are thought to activate a neural mechanism
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that generates intense panic in response to immediate threats such as physical pain,
asphyxia, or impending attack by a predator (Graeff, et al., 1996). Although distinct
serotonergic pathways are hypothesized to play a role in the response to each class of
stressor, each mechanism plays a common role in activating sympathetic arousal,
vigorous escape behavior, and analgesia (Graeff, 1993).
Physiological Effects of Stress
Sympathetic Nervous System. It is difficult to discuss stress responding without
devoting significant attention to the sympathetic nervous system. Activation of the
sympathetic nervous system is known to effect powerful short-term changes in the body,
largely through the release of catecholamines. Epinephrine and norepinephrine are most
commonly associated with this process which is thought to promote beneficial behavior in
situations of “fight or flight” (Udelsman and Holbrook, 1994). A cursory review of the
sympathetic effects on an organism reveals the utility of this system in the activation of
vigorous behavior. Among the changes induced by this response are increases in arterial
blood pressure, increased blood flow to active muscles, decreased blood flow to organs
not aiding intense motor activity, increased cellular metabolism, increased glycolysis in
muscles and the liver, as well as increased muscle tone (Guyton and Hall, 1996). The
specific role of the catecholamines in mediating the stress response will be discussed later.
The Hypothalamic-Pituitary-Adrenal Axis. The HPA axis is a set of structures in the
brain and peripheral nervous system regarded as an integral mediator of the stress
response. Acting in concert with the sympathetic nervous system, the primary function of
the HPA axis is to facilitate the rapid release of glucocorticoid hormones into the
bloodstream during stress responding (Chrousos, 1995; Herman, Prewitt, and Cullinan,
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1996). Much like the effects of catecholamines, glucocorticoids allow vigorous
activity by promoting glucose release in the liver, increased cardiovascular activity, and
deactivation of nonessential endocrine systems (Munck, Guyre, and Holbrook, 1984). In
essence, the HPA axis primes the body for adaptive behavior that benefits short-term
survival in situations that are acutely stressful or threatening. Additionally, the HPA axis
seems to function in the long-term as a physiological coping mechanism, a role mediated
by a feedback loop that will be described in greater detail later.
Stressors initiate stress responding at the level of the hypothalamus, the first
component in the triad of structures that comprise the HPA axis. Here, corticotropinreleasing factor (CRF) is released from neurons originating in the paraventricular nuclei
(Makara, Stark, Karteszi, Palkovits, and Rappay, 1981). CRF is then transported through
the hypophyseal portal system, arriving at the anterior pituitary gland, where it stimulates
the production of adrenocorticotropin, or ACTH (Hodges, 1984). ACTH is then secreted
into the bloodstream, eventually arriving at the adrenal cortex where it stimulates
increases in cyclic adenosine monophosphate (cAMP) levels and production of the
glucocorticoid cortisol (corticosterone in rats) (Honn and Chavin, 1977). At this level of
the HPA axis, cortisol is secreted into the bloodstream from the adrenal cortex.
Cortisol serves multiple functions in the central and peripheral nervous systems.
Noted mainly for its anti-inflammatory properties, cortisol is also a powerful
immunodepressant. Additionally, cortisol plays a role in maintaining water and
electrolyte concentrations, gastric secretions, as well as promoting lipid, carbohydrate and
protein metabolism (Simmons, Miles, Gerich, and Haymond, 1984). Cortisol also
induces short-term increases in metabolism, promoting vigorous “fight or flight” behavior
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as well as tissue repair in injured organisms, clearly adaptive effects with respect to
physical stress (Udelsman and Holbrook, 1994; Kudsk and Mirtallo, 1983).
Negative Feedback in the HPA Axis. Chronically elevated glucocorticoid levels have
been shown to adversely affect metabolic processes, disrupt the immune response, and
play a role in the etiology of depression and other neurobiological disorders (RebuffeScrive, Walsh, McEwen, and Rodin, 1992; Dhabhar and McEwen, 1997; Mizoguchi,
Yuzurihara, Ishige, Sasaki, Chui, and Tabira, 2001). Thus, there is an apparent need for a
regulatory mechanism that terminates stress responding, as continued elevation of
glucocorticoid levels is maladaptive (McEwen, De Kloet, and Rostene, 1986). Cortisol
plays an important role in regulating basal and stress-evoked levels of ACTH through the
initiation of a negative feedback loop involving the hypothalamus, pituitary,
hippocampus, amygdala, septum and other midbrain structures (McEwen, et al., 1986).
Corticosteroids have been shown to have a direct inhibitory effect at the level of the
hypothalamus and pituitary, resulting in decreased secretion of CRF and ACTH,
respectively (Jacobson and Sapolsky, 1991). Other brain structures, most notably the
hippocampus and frontal cortex have been shown to inhibit HPA axis activity by
decreasing CRF and vasopressin secretion (Jacobson and Sapolsky, 1991). Conversely,
certain nuclear groups of the amygdala have been shown to activate the HPA axis by
stimulating increases in ACTH and cortisol release (Van de Kar & Blair, 1999).
Monoaminergic Regulation of Stress
The monoamines are found throughout central and peripheral tissues and are subdivided into
two classes: the catecholamines and the indolamines. Both groups exert varying degrees of
influence on stress responding.
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Catecholamines: A Brief Overview. Norepinephrine and epinephrine, the
catecholamines most relevant to the study of stress responding, are secreted peripherally
by postganglionic sympathetic nerves and the adrenal medullae. In the central nervous
system, the bulk of norepinephrine is produced in the locus coeruleus, although various
nuclear groups of the hypothalamus, amygdala, and other groups synthesize the
neurotransmitter as well (Pacak, Palkovits, Kopin, and Goldstein, 1995). Dopamine, a
third catecholamine that plays a role in stress responding, is manufactured in
the brain primarily by the substantia nigra and surrounding nuclear groups.
Catecholamines and Stress. Generally, the catecholamines are thought to stimulate
activity in the HPA axis (Herman, et al., 1996). Exposure to a variety of physical and
psychological stressors has been shown to elevate levels of norepinephrine in the
hypothalamus, amygdala, and other brain structures intrinsically related to activation of
the HPA axis (Pacak, et al., 1995). Introcerebroventricular (ICV) injections of
norepinephrine and epinephrine have been shown to increase plasma ACTH levels and
induce an increase in hypophyseal portal levels of CRF (Szafarczyk, Malaval, Laurent,
Gibaud, and Assenmacher, 1987; Plotsky, 1987).
Lesion and stimulation studies have been integral to our understanding of
catecholaminergic systems in the HPA axis, as well. Chemical lesion of the ventral
noradrenergic bundle, a major adrenergic pathway innervating the hypothalamus, results
in a drastic decrease in blood levels of CRF as measured in the hypophyseal portal
system, as well as decreased hypothalamic levels of norepinephrine and epinephrine
(Guillaume, et al., 1987). Stimulation of the same nerve bundle has been shown to
increase plasma corticosterone levels in rats (Saphier and Feldman, 1989). Such findings
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suggest a stimulatory role of the catecholamines in HPA axis functioning (Cunningham
and Sawchenko, 1988; Cunningham, Bohn, and Sawchenko, 1990).
Serotonin and Stress
Since its discovery in the 1930s, serotonin (5-HT, 5-Hydroxytryptamine; see Figure 1)
has become the focus of intense research in diverse fields including biochemistry, psychology,
and neurophysiology. Initially detected in high concentrations in the gastrointestinal mucosa,
NH

HO

NH2

Figure 1: Serotonin
serotonin was later isolated in platelets, functioning as a vasoconstrictor upon its release into
clotting blood (Erspamer, 1966; Rapport et al., 1948). Additionally, it was discovered that
patients suffering from intestinal enterochromaffin tumor excreted relatively large
volumes of the serotonin metabolite 5-hydroxyindoleactic acid in urine, a prominent marker
that is still used in screening for gastrointestinal cancer today (Wilander, Lundqvist, and
Oberg, 1989). This excess secretion of 5-HT, termed carcinoid syndrome, produced
cutaneous flushing, diarrhea, bronchospasm, and right-sided valvular lesions, as well as
psychotic effects similar to those produced by lysergic acid diethylamide (LSD). This
behavioral link to LSD was one of the first pieces of data suggesting a presence of 5-HT in
the central nervous system. In fact, serotonin is present throughout the CNS, where it
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functions as a neurotransmitter, and in some cases, a neuromodulator, eliciting a wide range
of acute and generalized actions in multiple bodily systems.
Serotonin Receptor Subtypes
In evolutionary terms, serotonin is one of the oldest biologically active substances,
perhaps even predating the existence of adrenergic and cholinergic neurotransmitters
(Venter, et al., 1988). In addition to humans and other mammals 5-HT is also present in
mollusks, arthropods, insects, as well as some fruits and nuts (Feldman and Lee, 1985;
Tarchalska-Krynska and Kostowski, 1976). Interestingly, the structural features of the
serotonin molecule have been conserved over millions of years, while 5-HT receptors
themselves have evolved into pharmacologically distinct networks (Venter, et al., 1988).
Today, a concise system of categorizing 5-HT receptor subtypes has been developed.
There are currently seven families of 5-HT receptors, numbered 5-HT1-7. Further
subdivisions exist within these families (e.g., 5-HT1A,1B,1C) Of the families mentioned
above, 5-HT1, 5-HT2, and 5-HT3 receptors have been researched in greatest depth, and
will be discussed in relation to their relevance to the study of stress and anxiety.
The 5-HT1 Receptor Subtype: An Overview. 5-HT1 receptors are found throughout
the central and peripheral nervous system, where they share a common role in decreasing
serotonergic activity (Marcinkiewicz, Verge, Gozlan, Pichat, and Hamon, 1984; Radja,
Laporte, Daval, Verge, Gozlan, and Hamon, 1991; Hoyer, et al., 1994). The 5-HT1A, 1B,
and 1D receptors have been studied in greatest detail, and appear to function both
presynaptically and postsynaptically. In the former case, 5-HT1 receptors serve as
autoreceptors, reducing synthesis and firing rates of 5-HT neurons (de Montigny and
Blier, 1992; Middlemiss, Bremer, and Smith, 1988; Graeff, 1993). Postsynaptic 5-HT1
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receptors are found in various forebrain sites, especially the hippocampus, where they are
thought to have a hyperpolarizing effect, thereby reducing the effects of 5-HT in the
synapse. The 5-HT1C receptor subclass has been found to share sufficient features with
the 5-HT2 family that it has been renamed 2C, accordingly (Humphrey, Hartig, and Hoyer,
1993). Little is known about the 5-HT1E and 1F families, though they share many of the
primary features of the 5-HT1 family. Development of specialized ligands for these
receptors will facillitate subsequent pharmacological categorization.
Clinical Significance of the 5-HT1 Receptor Family. Selective and/or partial
agonists of the 5-HT1A receptor have proven efficacious in the treatment of depression
and anxiety, suggesting that both disorders have a common root involving serotonergic
function (Deakin, 1998). Buspirone (Buspar), the first clinically available drug of this
nature, is a selective partial agonist at the 5-HT1A receptor that has garnered attention as
a non-sedative anxiolytic, effective in the treatment of generalized anxiety disorder
(Gammans, Stringfellow, Hvizdos, Seidehammel, Cohn, Wilcox, et al., 1992). Notably,
the anxiolytic and antidepressant effects of buspirone and other 5-HT1A agonists are
generally only observed after one to three weeks of chronic administration. Such findings
suggest that a secondary mechanism, such as presynaptic autoreceptor downregulation
may be responsible for the therapeutic benefit seen after treatment with 5-HT1A agonists.
Behavioral Effects of 5-HT1 Receptor Ligands. Animal studies utilizing 5-HT1
ligands have produced findings that vary across experimental models. As mentioned
earlier, the delayed therapeutic effect of buspirone in humans seems to suggest that an
increase in 5-HT activity secondary to downregulation of presynaptic 5-HT1 receptors is
ultimately responsible for reducing anxiety. In rats, however, acute central and peripheral
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injections of the 5-HT1A agonist 8-OH-DPAT have been shown to attenuate stress
responding in the elevated T-maze, various restraint paradigms and the elevated plus maze
(Graeff, et al., 1996; McBlane and Handley, 1994; Kennett, Dourish, and Curzon, 1987).
Similarly, acute systemic administration of the 5-HT1A agonist buspirone has been shown
to reduce ultrasonic vocalization, while releasing suppressed locomotor activity in
response to foot shock in rats, both anxiolytic effects (Rowan, Cullen, and Moulton,
1990). Upon initial examination, these findings seem compatible with findings that 5-HT1
agonists are anxiolytic in humans. However, the delayed therapeutic effects seen in
humans suggest that a different mechanism, such as presynaptic autoreceptor
downregulation or postsynaptic upregulation, may be at work.
5-HT1 Receptors and Open-field Behavior. The open field is an experimental
environment that assesses animal behavior on a range of variables that include
locomotion, rearing, grooming, and body posture. Increases in locomotion and rearing
are classified as exploratory behavior and are commonly associated with anxiolysis.
Increases in grooming, or the presence of a creeping gait and elongated crawling posture
near the periphery of the field are regarded as anxiogenic behaviors. Head and body
shakes are also observed in the open field, but are typically regarded as artifacts of drug
administration rather than an indicator of a specific anxiolytic or anxiogenic effect.
The administration of a 5-HT1A agonist in rats has consistently been shown to alter
locomotion in the open field. Subcutaneous administration of the 5-HT1A agonists 8-OHDPAT, ipsapirone, and buspirone all reduced locomotion and rearing in the open-field,
both anxiogenic effects (Frances, Khidichian, and Monier, 1990, Kennett, et al., 1987).
Similarly, injections of the 5-HT1A agonists flesinoxan and 8-OH-DPAT both reduced
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instances of rearing, while increasing movement along the periphery of the open field,
effects deemed by the authors to be anxiogenic (Ahlenious, Larsson, and Wijkstrom,
1991). Though these studies suggest that administration of a 5-HT1A agonist results in
increased anxiety in the open field, contrary findings have been reported. Intrahippocampal injections of the 5-HT1A agonist buspirone have been shown to increase
exploratory behavior in the open field, as well as the elevated plus-maze (Kostowski,
Plaznik, and Stefanski, 1989).
5-HT1A Receptors and the HPA Axis. There is limited evidence to support an
interaction between HPA axis functioning and the 5-HT1A receptor. In low doses,
microinjections of the 5-HT1 agonist 8OH-DPAT into the PVN or third ventricles
resulted in decreased plasma levels of corticosterone, whereas high doses produced the
opposite effect (Welch, Farrar, Dunn, and Saphier, 1993). The latter finding has been
replicated, with 5-HT1 agonists consistently reported to increase CRF release
from the hypothalamus, followed by rises in serum levels of ACTH and corticosterone
(Feldman, Newman, Weidenfeld, 2000; Hemrick-Luecke and Evans, 2002).
Genetic Alteration of the 5-HT1A Receptor. Recent genetic manipulation of the 5HT1 receptor level has provided compelling evidence for a role of 5-HT1A receptors in
stress and anxiety. Three strains of knockout (KO) rats, altered to lack the 5-HT1A
receptor, have been shown to display increased anxiety in the open field, foot shock test,
and a range of behavioral conflict paradigms (Gross, Santarelli, Brunner, Zhuang, and
Hen, 2000). It should be noted, however, that differences in stress responding in 5-HT1A
KO rats seem to depend on the intensity of the stressor in certain strains of animals
(Olivier, Pattij, Wood, Oosting, Sarnyai, and Toth, 2001). That is, certain strains of 5-
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HT1A KO rats do not exhibit higher baseline anxiety, but display enhanced responses to
stressful stimuli, such as cage changes and induced hyperthermia (Olivier, et al., 2001).
The 5-HT2 Receptor Subtype: An Overview. The 5-HT2 receptor subclass is
regarded traditionally as a mediator of certain peripheral actions of 5-HT, which
include bronchoconstriction, platelet aggregation, and muscle contraction (Hoyer, et al.,
1994). Centrally, 5-HT2 receptors are likely involved in the mediation of anxiety,
depression, and schizophrenia. Currently, three subtypes of 5-HT2 receptors are
recognized (2A, 2B, and 2C)
Clinical Significance of the 5-HT2 Receptor Family. Several ligands of the
5-HT2 receptor have proven effective in the treatment of clinical disorders such as
depression and schizophrenia. The 5-HT2A receptor may play a role in the etiology of
schizophrenia, based on the success of the antipsychotic drug clozapine, a potent 5-HT2A
antagonist (Huttunen, 1995). Clozapine, also a dopamine D2 receptor antagonist, was an
integral factor in the development of the serotonin-dopamine antagonist model
of treatment for schizophrenia. This model called for the use of single compounds that
were both selective antagonists at the 5-HT2A receptor, as well as less potent blockers of
the D2 receptor (Huttunen, 1995). Risperidone, the first clinically available compound in
this evolving class of antipsychotics, has shown promise in reducing the positive and
negative symptoms of schizophrenia, without inducing the extrapyramidal symptoms
characteristic of traditional anti-dopaminergics (Huttunen, 1995).
5-HT2 antagonists have also shown promise recently in the treatment of clinical
depression. Nefazadone, a 5-HT2 selective antagonist, improved depressive symptoms
with therapeutic benefits similar to those seen with serotonin-selective reuptake inhibitors
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(SSRIs) and imiprimine, without inducing many of the adverse effects commonly seen in
other classes of antidepressants (Davis, Whittington, and Bryson, 1997). Mianserin, a
5-HT2A/2C antagonist, has also proven effective in preventing sexual dysfunction
associated with SSRIs when used in conjunction with the existing treatment regimen
(Aizenberg, Gur, Zemishlany, Granek, Jeczmien, and Weizman, 1997). Similarly,
mianserin positively augmented the symptoms of treatment-resistant depression when used
in concert with the SSRI fluoxetine (Maes, Libbrecht, van Hunsel, Campens, and Meltzer,
1999).
Behavioral Effects of 5-HT2 Receptor Ligands. 5-HT2 agonists and antagonists
have been tested extensively in several animal models of anxiety and stress. The findings
are frequently inconsistent, suggesting complex interactions between various brain
sites and 5-HT receptor subtypes in the mediation of stress and anxiety.
There are several studies that suggest decreased serotonergic activity at the 5HT2 receptor may be associated with decreased anxiety and stress responding. Many of
these studies involve the administration of a selective antagonist. Intraperitoneal
injections of SB242084, a selective brain-penetrating antagonist at the 5-HT2C receptor,
has been shown to increase social interaction in rats (Kennett, et al., 1997). Peripheral
administration of mianserin, a non-selective 5-HT2 antagonist, and SB 206553, a selective
2B/2C

antagonist, increased punished responding in the Vogel drinking test and increased

open-arm entries in the elevated plus-maze, both anxiolytic effects (Griebel, Perrault,
Sanger, 1997). In the rat ultrasonic vocalization test, social cohesion test, and the
elevated T-maze, peripherally administered 5-HT2A antagonists consistently produced
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anxiolytic effects as well (Schreiber, Melon, and De Vry, 1998; Rademacher, Anderson,
and Steinpreis, 2002).
Certain studies have found that increased serotonergic activity at the level of the 5HT2 receptor class results in anxiolysis. Intra-amygdala injections of the 5-HT2B agonist
BW723C86 increased social interaction in rats, an effect antagonized by oral pretreatment
with the 5-HT2B/2C antagonist SB 200646A (Duxon, Kennett, Lightowler, Blackburn, and
Fone, 1997). DOI, a nonselective agonist of the 5-HT2 receptor, was found to reduce tailpinch-induced stress responding when injected subcutaneously, or by a combination of
subcutaneous and intracerebroventricular administration (Hawkins, Uzelac, Baumeister,
Hearn, Broussard, and Guillot, 2002).
In the open field, limited findings suggest that increased serotonergic activity at the
5-HT2 receptor correlates with a decrease in anxiety. DOI, a nonselective 5-HT2 agonist,
increased exploratory behavior in the open field, an effect which was fully antagonized by
the 5-HT2A/2C antagonist ritanserin (Kaur and Ahlenius, 1997). Similarly, microinjections
of nefazadone, a nonselective 5-HT2 antagonist, into the basolateral amygdala,
potentiated the anxiogenic effects of inferior colliculus stimulation in the open field
(Maisonnette, Villela, Carotti, and Landeira-Fernandez, 2000).
5-HT2 Receptors and the HPA Axis. DOI, m-CPP, Ro 60-0175 and quipazine have
been shown to increase serum concentrations of corticosterone in rats (HemrickLuecke and Evans, 2002; Raghavendra and Kulkarni, 2000;). This effect can be abolished
by co-administration of the highly selective 5-HT2A antagonist M100907, but is only
marginally affected by the selective 5-HT2C antagonist SB 242084, suggesting a
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prominent role of the 2A receptor in activating the HPA axis (Hemrick-Luecke and Evans,
2002).
Genetic alteration of the 5-HT2 receptor. Limited studies involving genetic
manipulation of 5-HT2 receptors have provided support for serotonergic involvement in
stress responding, particularly with regard to the HPA axis. A recent finding has shown
that deletion of the 5-HT2C receptor leads to increased plasma concentrations of ACTH
and corticosterone in rats subjected to repeated cage changes, suggesting
hyperresponsiveness of the HPA axis in these animals (Chou-Green, Holscher, Dallman,
and Akana, 2003).
The 5-HT3 Receptor Subtype: An Overview. The 5-HT3 receptor is the only
member of the 5-HT family that operates as a ligand-operated ion channel, directly
influencing potentials via stimulation of cation-selective channels (Derkach, Suprenant,
and North, 1989; Malone, Peters, and Lambert, 1991). 5-HT3 receptors are found at
multiple locations within the peripheral and central nervous systems. Locations relevant
to the study of stress and anxiety will be discussed subsequently.
Clinical Significance of the 5-HT3 Receptor Family. The 5-HT3 receptor is well
known for its role in the mediation of the emetic response. A family of selective 5-HT3
antagonists that includes granesitron, ondansetron, tropisetron, and dolasetron has proven
highly effective in the treatment of emetic disorders. It has been suggested that these
drugs operate by central antagonism of 5-HT3 receptors in the chemoreceptor trigger-zone
of the area postrema (Higgins, Kilpatrick, Bunce, Jones, and Tyers, 1989), though a
peripheral mechanism mediated in the upper gastrointestinal tract through vagal afferents
is likely also involved (Andrews, Davis, Bingham, Davidson, Hawthorn, and Maskell,
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1990). Recent research suggests that the 5-HT3 family of receptors is also involved in the
etiology of a diverse array of clinical disorders that include anxiety, depression,
psychosis, chronic pain, as well as drug and alcohol abuse (Greenshaw and Silverstone,
1997).
5-HT3 Ligands and Stress. Compounds that selectively target the 5-HT3
receptor have been tested extensively in various animal models of physical and
psychological stress. Peripheral administration of selective 5-HT3 antagonists has been
shown to reduce stress responding, in terms of both physiology and behavior, suggesting
an anxiolytic effect as a result of reduced serotonergic activity at the 5-HT3 receptor. In
rats, intraperitoneal injection of the 5-HT3 antagonists ICS 205-930, GR 28032F, and
ondansetron decreased stress-induced prolactin release, an anxiolytic effect (Jorgensen,
Knigge, and Warberg, 1992, Nonaka, 1999). Ondansetron has also been shown to
increase exploratory behavior in the open field, as well as negating the anti-exploratory
effects of caerulein, a decapeptide, in the elevated plus-maze (Stefanski, Palejko,
Kostowski, and Plaznik, 1992; Vasar, Peuranen, Oopik, Harro, and Mannisto, 1993).
There is a growing body of evidence that 5-HT3 antagonists may exert their
anxiolytic effects centrally. Injections of the 5-HT3 antagonists tropesitron or
ondansetron into the hippocampus and nucleus accumbens produced anxiolytic-like
behavioral effects in the Vogel conflict test and the open field (Stefanski, Palejko,
Bidzinski, Kostowski, and Plaznik, 1993). These antagonists also suppressed stress
responding induced by electroconvulsive shock (Kostowski, Plaznik, Nazar, and Jessa,
1995).
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Theoretical Bases for Current Research
5-HT1, 5HT2 and perhaps 5-HT3 receptors have been implicated in stress
responding. Previously, we have demonstrated that subcutaneous injection of the 5HT2A/2C agonist, DOI, dose-dependently reduces tail pinch-induced stress responding in
rats (Hawkins, et al., 2002). Additional unpublished data from our lab show that this
effect can be reversed in a dose-dependent fashion by subcutaneous co-administration of
the 5-HT2A/2C antagonist Ketanserin. Further, we have observed that stress responding is
not affected when 5-HT or DOI are injected into the cerebral ventricles, dorsal
periaquaductal grey, or the amygdala. Therefore, the anxiolytic action of DOI appears to
be mediated by a peripheral mechanism despite the fact that DOI and ketanserin cross the
blood-brain barrier.
Other findings support the theory that increased serotonergic activity at the 5-HT2
receptor results in decreased anxiety. Intra-amygdala microinjections of the 5-HT2B
agonist BW723C86 have been shown to increase social interaction in the rat (Duxon, et
al., 1997). Similarly, intraperitoneal injections of the 5-HT2 agonists TFMPP and mCPP
have been shown to impair inhibitory avoidance in the elevated T-maze, an anxiolytic
effect (Mora, et al., 1997). In the open field, DOI has been shown to increase exploratory
behavior, an effect fully antagonized by the 5-HT2A/2C antagonist ritanserin (Kaur and
Ahlenius, 1997).
In addition to the aforementioned pharmacological studies, genetic manipulation of
the 5-HT2C receptor has provided further support for the role of this receptor as an integral
mediator of negative feedback in the HPA axis (Chou-Green, et al., 2003).
The current study investigated further the role of the 5-HT2 receptor in the mediation of
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stress responding in the rat. Experiments employed selective 5-HT2A and 5-HT2C
antagonists in an effort to block the stress-related effects of peripherally administered DOI.
Such experiments were intended to clarify the relative importance of these two receptor
subtypes in mediating the behavioral effects of DOI.
Hypotheses
1. The non-selective 5-HT2 agonist, DOI, injected subcutaneously, will decrease tail
pinch-induced stress responding in rats.
2. The effect of DOI on tail pinch-induced stress responding will be reduced by
peripheral co-administration of the selective 5-HT2A antagonist, spiperone.
3. The effect of DOI on tail pinch-induced stress responding will be reduced by
peripheral co-administration of the selective 5-HT2C antagonist, SDZ SER 082.
4. Spiperone and SDZ SER 082 will have no effect on stress responding when
administered alone.
5. Simultaneous administration of spiperone and SDZ SER 082 will result in greater
antagonism of DOI’s effects than that of either antagonist administered alone.
6. Subcutaneous injection of DOI will have an anxiolytic effect on animal behavior in the
open field.
7. The effect of DOI on open field behavior will be reduced by spiperone, SDZ SER 082,
or a combination of the two antagonists.
8. The administration of DOI, spiperone, SDZ SER 082 and combinations thereof,
will not impair general motor function, as measured by rotarod performance and
ambulation in the open field.
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Drugs
Determination of Doses. In the case of DOI, drug was administered at doses that were
based on previous work conducted in our lab. We have seen an effect of medium and high
doses (0.5 and 1.0 mg/kg) of DOI on stress responding, with no effect following low dose
injections (0.1 mg/kg) (Hawkins, et al., 2002). Doses of spiperone and SDZ SER 082 were
determined based on an extensive search of the literature (see Tables 1 and 2). Highest
priority was assigned to literature relevant to the study of stress and anxiety, particularly
studies that employed subcutaneous administration of spiperone or SDZ SER 082. Studies
utilizing alternate routes of systemic administration, such as interperitoneal injections, were
considered, as well. Lastly, low priority was assigned to literature unrelated to stress, but
that employed relevant compounds, a systemic route of administration and behavioral
dependent variables.
5-HT2A/2C Agonist. DOI [(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2 aminopropane;
Figure 2] is a potent serotonergic agonist with high affinity for the 2A and 2C receptors.
NH2

O

O
I

Figure 2: DOI
This compound has been tested in several models of anxiety and stress mentioned
previously and is known to readily cross the blood-brain-barrier (BBB). DOI HCl was
purchased from Sigma-Aldrich Corp. (St. Louis, MO).
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5-HT2A Antagonist. Spiperone (8-[3-(p-fluorobenzoyl)propyl]-1-phenyl-1,3,8triazaspiro[4.5]decan-4-one; Figure 3; Table 1) is classified as an antipsychotic with high
affinity for 5-HT2A receptors. It is also a selective D2 antagonist and a weak antagonist of
the 5-HT1A receptor. It has been tested sparingly in animal models of anxiety and stress.

O
NH
O

N
N

F

Figure 3: Spiperone
Due to the low solubility of spiperone in saline, it frequently has been administered as a
suspension (e.g., Fujikawa, 1993, 1995; Kurashima, 1994, 1995; Matsumoto, 1988,
1989). The same method was employed in the current study. Spiperone HCl was
purchased from Tocris Cookson Inc. (Ellisville, MO).
Table 1: References used to determine dose range for spiperone
Article Author
Berendsen, et al., (1989)
Done & Sharp, (1992)
Fregly & Rowland,(1988)
Fujikawa, et al., (1995,
1996)
Gartside & Cowen (1990)
Inoue, et al., (1996)
Kennett, et al., (1987)
Kimura, et al., (1991)
Kostrzewa & Kastin, (1993)
Kurashima, et al., (1994)
Kurashima, et al., (1995)

Dependant Variable
Lip retraction
Hippocampal NE release
Isoproterenol consumption
Yawning

Dose Range
0.04-0.4 mg/kg
0.2-1.0 mg/kg
0.1 mg/kg
0.5 mg/kg

Route
SC
SC
SC
SC

ACTH release
Conditioned freezing
Restraint stress
Yawning
Catalepsy
Yawning, Oral Stereotopy,
Body Temperature
Prolactin secretion

1.0 mg/kg
0.1-1.0 mg/kg
0.1 mg/kg
0.5 mg/kg
0.3 mg/kg
0.5 mg/kg

IP
SC
SC
SC
SC
SC

0.5 mg/kg

SC
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Table cont.
Matsumoto, et al., (1988;
1989)
Ossowska, et al., (1982)
Rittenhouse, et al., (1994)
Rittenhouse, et al., (1991)
Schreiber, et al., (1993)
Sobrian, et al., (2003)
Yamada, et al., (1986)

Yawning, prolactin secretion

0.5 mg/kg

IP/SC

Catalepsy
ACTH secretion
Renin secretion
Ethanol preference
Grooming, oral stereotopy,
locomotion
Post-decapitation convulsions

0.2 mg/kg
0.01-0.1 mg/kg
0.01-0.1 mg/kg
0.05 mg/kg
0.06-1.0 mg/kg

SC
SC
SC
SC
SC

2.0 mg/kg

SC

5-HT2C Antagonist. SDZ SER 082 ((+)-cis-4,5,7a,8,9,10,11,11a-Octahydro-7H-10methylindolo[1,7-bc][2,6]-naphthyridine; Figure 4; Table 2) is a highly selective
compound at the 5-HT2B/2C receptor with a very low affinity for 5-HT1A receptors. SDZ
SER 082 has been used extensively in an effort to differentiate the behavioral effects
mediated by the 5-HT2A and 5-HT2C receptors. Notably, it has proven effective in
blocking behavior induced by serotonergic agonists at the 5-HT2 receptor, in various
models of stress, as well as behavioral research unrelated to stress. SDZ SER 082
fumarate was purchased from Tocris Cookson Inc (Ellisville, MO).
N

N

Figure 4: SDZ SER 082
Table 2: References used to determine dose range for SDZ SER 082
Article Author

Dependent Variable

Goudie, et al., (1998)

Drug discrimination
(clozapine)
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Dose Range

Rout
e
0.25-1.0 mg/kg SC

Table cont.
Koskinen, et al., (2000)
Krebs-Thompson, et al.,
(1998)
Mora, et al., (1997)
Ouagazzal, et al., (2001)
Varty, et al., (1999)
Willins & Meltzer, (1997)

Five-choice serial reaction
time task
Locomotor activity

0.1-1.0 mg/kg

SC

0.5-1.0 mg/kg

SC

Anxiety (elevated T-maze)
Prepulse inhibition
Prepulse inhibition
DOI-induced head twitches

0.1-1.0 mg/kg
1.0 mg/kg
1.0 mg/kg
0.3 mg/kg

SC
SC
SC
SC
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Method
The current study was composed of five experiments, each of which followed the same
general format. Procedures common to all of the experiments will be described collectively,
followed by specific methodological alterations unique to each experiment.
All drugs were stored at room temperature in their original containers until needed.
Drugs were weighed at the start of each testing day and were diluted in sterile physiological
saline (0.9%) to the desired concentration.
Sixteen male Sprague-Dawley rats between the ages of 8 and 12 weeks were used for
each experiment. Animals were obtained from the Division of Laboratory Animal Medicine
of Louisiana State University. Animals were housed individually with water and laboratory
chow available ad-lib. The room in which the animals were housed were held at a constant
temperature of 22 degrees C with lighting set on a 12-hour light/dark cycle, beginning at
07:00 hr.
Each experiment employed a within-groups design, consisting of three drug conditions
and a control condition in which animals received saline vehicle. Order of presentation of
experimental conditions was manipulated employing a modified Latin square design.
Testing occured at three day intervals in an effort to maximize recovery time in the event
that tail damage occurred during observation.
Experiment One: Peripheral DOI (5-HT2A/2C Agonist)
Animals were randomly assigned to one of four experimental conditions: DOI (0.1
mg/kg, 0.5 mg/kg and 1.0 mg/kg) and a saline control.
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Experiment Two: Peripheral Spiperone (5-HT2A Antagonist)
Animals were randomly assigned to one of four experimental conditions: Spiperone (0.1
mg/kg, 0.5 mg/kg, and 1.0 mg/kg) and a saline control.
Experiment Three: Peripheral SDZ SER 082 (5-HT2C Antagonist)
Animals were randomly assigned to one of four experimental conditions: SDZ SER 082
(0.1 mg/kg, 0.5 mg/kg, and 1.0 mg/kg) and a saline control.
Experiment Four: DOI + Single Antagonist
Animals were randomly assigned to one of four experimental conditions: DOI alone,
DOI + Spiperone, DOI + SDZ SER 082, and a saline control.
Determination of Doses. Doses of DOI, spiperone and SDZ SER 082 were
selected based on the outcome of Experiments 1, 2 and 3. In the case of DOI, the lowest
overall effective dose in Experiment 1 was administered. The highest dose of each
antagonist was used, provided that no dose of either drug was found to significantly alter
stress responding when administered alone. If an antagonist was found to alter stress
responding when administered alone, the highest ineffective dose was used in Experiment 4.
Experiment Five: DOI + Multiple Antagonists.
Doses of DOI, spiperone, and SDZ SER 082 were determined based on the outcome of
experiments 1, 2 and 3. Animals were assigned to one of four experimental conditions: DOI
alone, spiperone + SDZ SER 082, DOI + spiperone + SDZ SER 082, and a saline control.
Determination of Doses. As in Experiment 4, the lowest overall effective dose of
DOI was administered (based on the results of Experiment 1). Similarly, the highest
ineffective doses of both antagonists were co-injected with DOI in Experiment 5.
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General Procedure
Rater Training Criterion. Data collectors were trained to 85% accuracy in both
tail pinch and open field observations. Animals used for training purposes were not
included as subjects in subsequent experiments. Data collectors learned to properly
handle the animals, apply stressors, and record behavioral data. Training occurred in the
presence of an experienced (previously trained) rater, who also observed and recorded
behavioral data. Data collectors were required to successfully record each behavior to a
degree of 85% concordance with the experienced rater in two consecutive 4-minute trials.
These criteria applied to both tail pinch and open field observations.
Single Drug Injection Procedure. Prior to receiving an injection, animals were taken
from their home cages, weighed, and their tails marked for tail pinch (as described
in greater detail later). Animals were restrained by hand and received a single
subcutaneous injection of drug or saline vehicle at the base of the neck. The total volume
of drug injected was based upon the individual animal’s weight and was administered in a
volume of 1.0 ml per kg. After receiving injections, animals were returned to their home
cages for a period of thirty minutes. At the conclusion of this waiting period, animals were
placed in the tail pinch cage and exposed to the stressor described below.
Multiple Drug Injection Procedure. Combination agonist/antagonist injections were
administered in a volume of saline calculated based on the individual animal’s weight (1.0
ml per kg). The concentration of each drug was increased so that the total volume of
injected solution was equal to that of single-injection animals. After receiving an injection,
animals were returned to their home cages for a thirty-minute waiting period, prior to
testing.
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Testing
All experimental animals were observed under two conditions: the tail pinch
stressor and the open field. Observation in the tail pinch cage always preceded the
open field.
The Tail Pinch Stressor. Prior to injection, animals’ tails were marked with a felttipped marker at a diameter of 4.3 mm. These measurements were made using standard
metal calipers. The tails were remeasured and remarked prior to each tail pinch session
to control for possible differences in diameter due to edema or growth of the animals.
The tail pinch cages were cleaned and dried before each trial. Animals were
placed in the center of the suspended wire cage, the length of the tail was guided
through the cage’s floor, and a clamp was applied at the previously marked diameter.
The clamp was fashioned from hemostatic forceps, padded with plastic tubing to avoid
tail damage. Animals were observed for a period of four minutes. After observation, the
forceps were removed and the animals were returned immediately to their home cages.
Dependent variables in the tail pinch. Animals’ behavior was assessed on the
following five variables during exposure to the tail pinch stressor:
1. Oral behavior directed at food was defined as the total
amount of time an animal licked, gnawed, or chewed laboratory chow.
2. Oral behavior not directed at food was defined as the
amount time an animal licked or bit the cage, or engaged in oral behavior
without having food in its mouth (e.g., chattering of the teeth).
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3. Grooming was defined as the amount of time an animal engaged in
licking its own body, fluffing or wiping its facial hair or whiskers with the
forepaws, or directing any oral behavior toward its tail.
4. Vocalizations were defined as the number of vocal emissions over the
course of the testing period.
5. Fecal boli were recorded as the number of boli produced over the course of
the testing period.
After completion of the tail pinch, two measures were made of the animals’ oral
behavior directed toward lab chow during the testing period:
6. Eating was defined as the amount of lab chow an animal ingested over the
course of the testing period. This measure was calculated by subtracting
the post-test weight of the lab chow from the pre-test weight.
7. Gnawing was defined as the amount of lab chow that was shredded, but not
ingested by the animal over the course of the testing period. This measure
was made by weighing the shredded chow that fell through the grating of the
cage during testing.
Open Field Testing. Forty-five minutes after injection (roughly ten minutes after the
conclusion of the tail pinch), animals were removed from their home cages and placed
in the open field for observation. The open field is an open-topped, Plexiglas box
measuring 2’x2’x2’. The floor of the apparatus is divided into four quadrants, each a 12”
square. A 75-watt light bulb is positioned directly above so that it shines down into the
open field. All animals were placed in the same predetermined quadrant and
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were observed for a period of four minutes. Following open field testing, animals
were returned to their home cages.
Dependent Variables in the Open Field. Behavioral observation in the open field
involved measurement of the following five variables:
1. Line crosses were defined as the number of times an animal passed
completely (all paws) into a different quadrant of the open field.
2. Rearing was defined as any instance in which an animal lifted both front
paws simultaneously from the floor of the open field.
3. Head shakes were defined as any instance in which an animal vigorously
shook its head from side to side.
4. Wet dog shakes were defined as any instance in which an animal shook its
head in combination with the upper torso.
5. Freezing was defined as the total amount of time an animal was completely
motionless, with the exception of breathing.
Rotarod. Twenty-four hours after the conclusion of the final day of tail pinch and
open field testing, each animal was trained on the rotarod apparatus. The rotarod
consists of a textured steel drum (7.2 cm in diameter) that rotates at adjustable speeds set
by the experimenter. During training and testing, the rotarod was set to rotate at a
velocity of 10 RPM. Animals received repeated trials on the rotarod until the training
criterion of thirty seconds (without falling off) was met. Animals unable to reach the
training criterion in twelve successive trials were excluded from subsequent testing.
Rotarod testing occurred twenty-four hours after training. Animals meeting the
training criterion were administered drug or saline based on the experimental condition
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assigned to them on the first day of stress testing. Injections were administered as
previously described and animals were returned to their home cages. Thirty minutes
later, animals were taken from their home cages and placed upon the rotarod apparatus.
Animals were allowed to continue walking on the rotarod until thirty seconds passed, or
the animal fell off, whichever occurred first.
Operational Definition of Anxiolytic and Anxiogenic Effects. Anxiety was inferred
when behavior occurred as a result of the imposition of a stressor upon an animal.
Consistent with convention in the existing literature (e.g. Adamec, Bartoszyk, and Burton,
2004; Adamec, Creamer, Bartoszyc, and Burton, 2004; Heilig, 2004; Sanchez, Gruca, Bien,
and Papp, 2003; Haller and Bakos, 2002; Maslova, Bulygina, and Markel, 2002; Clark, et
al., 2002; Radulovic, Ruhmann, Liepold, and Spiess, 1999), an “anxiolytic” effect was
defined as a reduction in behaviors evoked by a stressor, whereas an “anxiogenic” effect was
defined as an augmentation of such behaviors.
Tail Pinch. An increase in the following behaviors was interpreted as evidence of
anxiogenesis in the tail pinch condition: eating, gnawing, oral behavior directed at food, oral
behavior not directed at food, grooming, vocalizations, and defecation.
Open Field. In the open field, an increase in freezing behavior was regarded as
evidence of anxiogenesis. Increases in line crosses and rearing were considered anxiolytic
effects. The occurrence of head and body shakes was regarded as a nonspecific effect of 5HT ligands unrelated to the stress response.
Rotarod. Rotarod performance was used to assess general motor function and was
considered to be unrelated to the stress response.
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Recording Data. Any behavior involving a timed measure was recorded to the
nearest hundredth of a second, with the exception of the rotarod, which was measured
to the tenth of a second. Any variable measured according to weight, such as eating and
gnawing, was measured in grams and recorded to the nearest hundredth of a gram.
Statistical Analyses
Data collected in the tail pinch and the open field were analyzed using Multivariate
Analysis of Variance (MANOVA). Data collected on the rotarod were analyzed
separately by univariate analysis (ANOVA). Rotarod data were not included in the
MANOVA because some animals were unable to meet the training criterion, resulting in a
lower number of data points relative to other behaviors recorded in the tail pinch and open
field.
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Results
An analysis of tail pinch data revealed that oral behavior directed at food (OB w/ food)
was the predominant behavioral response to tail pinch stress. On average, animals spent
approximately 80 of a possible 240 seconds engaged in oral behavior directed at food.
However, 36% of the animals did not exhibit any OB w/ food under saline conditions.
Inclusion of these zeroes in our initial analysis resulted in an inflated error term, and a
concomitant reduction of statistical significance in our analyses. In experiments 4 and 5, this
inflation led to a diminution of statistical significance with regard to DOI relative to saline.
Thus, a post-hoc exclusionary criterion of 2 seconds was set for OB w/ food in the saline
condition. To be included in the secondary (post-culling) analyses, an animal must have
exhibited more than 2 seconds of OB w/ food in the saline condition. Animals not meeting
this criterion were culled from further analyses. Results of both analyses are included in the
following sections. For the sake of simplicity, excluded animals will be referred to as nonresponders in the subsequent discussion.
Statistical Analysis
Statistical analyses were conducted using SPSS (Statistical Package for the Social
Sciences, V. 10.0 for Windows). Tail pinch and open field behaviors were analyzed by
MANOVA. Rotarod data were analyzed separately by ANOVA.
Primary Analysis. Prior to exclusion of non-responders, data were analyzed to
determine if drug condition significantly affected behavioral responses to stress. The
results of each MANOVA are summarized in the following sections. In each experiment,
drug condition was the independent variable. Dependent variables were outlined in
previous sections and are listed individually in the following tables. Prior to application
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of the exclusionary criterion, n for each experiment was as follows: 15 (Exp. 1), 16 (Exp
2), 16 (Exp. 3), 15 (Exp. 4), and 16 (Exp. 5).
Secondary Analysis. After implementing an exclusionary criterion, n for each
experiment was reduced to the following: 12 (Exp. 1), 10 (Exp. 2), 10 (Exp. 3), 8 (Exp.
4), and 10 (Exp. 5). In an effort to achieve roughly equivalent n in each experiment,
animals were added to supplement experiments 4 and 5, bringing the final n in these
experiments to 11 and 13, respectively. These animals were subject to identical
methodological considerations given prior groups and were assigned to first-day drug
conditions in a manner designed to compensate for excluded data.
Experiment 1
Primary Analysis. Experiment 1 established a dose-response curve for DOI. The
overall MANOVA was significant [F(39, 107)=2.84, p=.000], using Wilk’s criterion.
The resulting univariate ANOVAs for each dependent variable are included in Table 3.
Variables that differed significantly across at least one experimental condition are
denoted with an asterisk.
Secondary Analysis. As was the case in the primary analysis, the overall MANOVA
for the four experimental conditions was found to be significant [F(39,96)=2.38, p=.000].
The secondary univariate analysis is summarized in Table 3.
Table 3: Experiment 1 Univariate ANOVAs by Behavior
Primary
Behavior
Eating
Gnawing
Oral Behavior Directed
at Food*

df
3
3
3

F
1.77
0.60
5.01
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p
0.16
0.62
0.004

Secondary
F
1.95
0.65
7.12

p
0.14
0.59
0.001

Table cont.
Oral Behavior Not
Directed at Food
Grooming
Vocalizations
Boli (Tail Pinch)
Line Crosses
Rearing*
Head Shakes*
Body Shakes
Boli (Open Field)
Freezing

3

0.23

0.88

1.64

0.19

3
3
3
3
3
3
3
3
3

1.35
1.63
0.67
2.67
12.05
6.65
2.15
0.30
2.25

0.27 2.52
0.19 1.00
0.57 0.73
0.06 2.70
0.000 10.60
0.001 5.21
0.10 2.20
0.82 0.00
0.09 2.31

0.07
0.40
0.54
0.057
0.000
0.002
0.10
1.00
0.09

Experiment 1 post hoc analysis. Primary post hoc analyses revealed that DOI altered
responding in the following three behavioral variables: oral behavior directed at food,
rearing, and head shakes. Secondary analysis revealed significant findings for the same
three variables: oral behavior directed at food, rearing, and head shakes.
Oral behavior directed at food (Figures 5 and 6). Primary and secondary analysis
generated statistically similar findings with respect to oral behavior directed at food. OB w/
food was reduced by the middle (pprimary=.010; psecondary=.003) and high (pprimary=.002;
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Figure 5: OB w/ Food (Exp. 1 Primary Analysis)
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psecondary=.000) doses of DOI, relative to saline. OB w/ food was also reduced, relative to
low-dose DOI, by middle (pprimary=.032; psecondary=.012) and high (pprimary=.009; psecondary=.002)
doses of DOI.
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Figure 6: OB w/ Food (Exp. 1 Secondary Analysis)
Rearing (Figures 7 and 8). As was the case with OB w/ food, primary and secondary
analyses of rearing yielded similar results. Rearing was reduced by middle (pprimary=.000;
psecondary=.001) and high (pprimary=.001;psecondary=.001) doses of DOI, relative to saline.
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Figure 7: Rearing (Exp. 1 Primary Analysis)
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Rearing was also reduced by middle (pprimary=.000; psecondary=.000) and high
(pprimary=.000; psecondary=.000) doses of DOI, relative to low-dose DOI.
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Figure 8: Rearing (Exp. 1 Secondary Analysis)
Head Shakes (Figures 9 and 10). Head shaking was increased by the middle dose of
DOI relative to saline (pprimary=.000; psecondary=.000), low-dose DOI (pprimary=.001;
psecondary=.003), and high-dose DOI (pprimary=.003; psecondary=.007). Frequency of head shakes
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Figure 9: Head Shakes (Exp. 1 Primary Analysis)
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was not affected by the low or high doses of DOI, relative to controls, in either the primary
or secondary analyses.
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Figure 10: Head Shakes (Exp.1 Secondary Analysis)
Experiment 2
Primary/secondary Analyses. Experiment 2 examined the dose-response profile of
the 5-HT2A antagonist, spiperone. Primary analysis by MANOVA revealed that
spiperone did not significantly alter behavioral responding when administered alone
[F(36,145)=1.35; p=.11]. This was also the case for the secondary MANOVA,
[F(33,77)=1.17, p=.284.
Experiment 3
Primary/secondary Analyses. Experiment 3 evaluated the possible behavioral
effects of the 5-HT2C antagonist, SDZ SER 082. As with spiperone, 5-HT2C antagonism
alone did not affect behavioral responses to stress based on the primary analysis by
MANOVA [F(33,148)=1.02, p =.45]. Similarly, the secondary MANOVA was not
statistically significant, [F(33,77)=1.01, p=.466.
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Experiment 4
Dose Selection. Experiment 4 examined the possibility that the effects of DOI on
stress-induced behavior might be reduced using a single selective antagonist. Doses for
DOI, spiperone (2A antagonist), and SDZ SER 082 (2C antagonist) were chosen based
on findings from Experiments 1, 2, and 3. In the case of DOI, the middle dose (0.5
mg/kg) was selected based on the fact that this dose of DOI produced behavioral effects
that were statistically indistinguishable from high-dose DOI. Therefore, it was
reasonable to conclude that behaviors affected by the middle dose of DOI had a greater
likelihood of being antagonized in Experiment 4.
Appropriate doses of spiperone and SDZ SER 082 were determined based on
findings from Experiments 2 and 3. Because neither drug was shown to alter
behavioral responding when administered alone, the highest dose (1.0 mg/kg) for each
drug was selected.
Analyses. The primary MANOVA for the four experimental conditions was
significant, [F(39,131)=3.24, p=.000], as was the secondary MANOVA [F(36,86)=1.82,
p=.012]. The resulting univariate ANOVAs are included in Table 4 below. Behaviors
that differed significantly across at least one experimental condition are denoted with an
asterisk.
Table 4: Experiment 4 Univariate ANOVAs by Behavior
Primary
Behavior
Eating
Gnawing
Oral Behavior
Directed at Food*

df
3
3
3

F
0.25
0.73
2.24
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p
0.86
0.54
0.09

Secondary
F
0.60
0.05
4.00

p
0.62
0.99
0.01

Table cont.
Oral Behavior Not
Directed at Food
Grooming
Vocalizations
Boli (Tail Pinch)
Line Crosses*
Rearing*
Head Shakes*
Body Shakes
Boli (Open Field)
Freezing*

3

1.73

0.17

0.80

0.50

3
3
3
3
3
3
3
3
3

2.18
1.85
0.71
7.52
5.65
7.38
1.00
18.83
0.64

0.10
0.15
0.55
0.00
0.00
0.00
0.40
0.59
0.00

0.37
2.03
0.88
3.26
2.66
4.44
0.50
5.07

0.77
0.13
0.46
0.03
0.06
0.00
0.69
0.00

Experiment 4 Post Hoc Analyses. Primary and secondary post hoc analyses generated
different results for Experiment 4. Primary post hoc analyses revealed that drug
conditions altered four behavioral variables: line crosses, rearing, head shakes, and freezing.
Secondary post hoc analyses also indicated that drug conditions affected responding across
four behavioral variables. However, these four variables differed slightly from the primary
post hoc analyses: oral behavior directed at food, line crosses, head shakes, and freezing.
Oral Behavior Directed at Food (Figure 11). Secondary analysis revealed the OB
w/food was reduced, relative to saline, by DOI (p=.007), DOI + spiperone (p=.008), and
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Figure 11: OB w/ Food (Exp. 4 Secondary Analysis)
38

DOI + SDZ SER 082 (p=.007). That is, neither antagonist reversed the DOI-induced
reductions in oral behavior.
Line crosses (Figures 12 and 13). In both the primary and secondary analyses,
injections of DOI + SDZ SER 082 resulted in decreased line crossing relative to saline
(pprimary=.000; psecondary=.012). In the primary analysis, injections of DOI + SDZ SER 082
were also shown to decrease line crossing relative to DOI alone (p=.026). Primary analysis
also showed that DOI + spiperone increased line crossing relative to DOI (p=.044).
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Figure 12: Line Crosses (Exp. 4 Primary Analysis)
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Figure 13: Line Crosses (Exp. 4 Secondary Analysis)
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Rearing (Figure 14). Primary analysis indicated that injections of DOI reduced rearing,
relative to saline (p=.006), as did DOI + spiperone (p=.008), and DOI + SDZ SER 082
(p=.000). Neither antagonist was able to reverse the DOI-induced reduction of rearing.
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Figure 14: Rearing (Exp. 4 Primary Analysis)
Head shakes (Figures 15 and 16). In the primary and secondary analyses, DOI
increased head shakes relative to both saline (pprimary=.006; psecondary=.004) and DOI +
SDZ SER 082 (pprimary=.006; psecondary=.004), as did DOI + spiperone (p=.000), which
suggests that the 5-HT2C antagonist was able to reverse DOI-induced head shaking. Both
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Figure 15: Head Shakes (Exp. 4 Primary Analysis)
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primary and secondary analyses indicated spiperone was ineffective in blocking DOIinduced head shaking.
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Figure 16: Head Shakes (Exp. 4 Secondary Analysis)
Freezing (Figures 17 and 18). Primary and secondary analyses generated the same
findings with respect to freezing. Injections of DOI + SDZ SER 082 resulted in increased
freezing relative to saline (pprimary=.000; psecondary=.006), DOI (pprimary=.000;
psecondary=.001), and DOI + spiperone (pprimary=.000; psecondary=.004).
120

100

Freezing (s)

80

60

40

20

0
SALINE

DOI 0.5

DOI + SPIP

DOI + SDZ

Drug Condition

Figure 17: Freezing (Exp. 4 Primary Analysis)
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Figure 18: Freezing (Exp. 4 Secondary Analysis)
Experiment 5
Experiment 5 examined the effects of DOI on stress-induced behavior when coadministered with a combination of 5-HT2A and 5-HT2C antagonists. The overall primary
MANOVA was significant F(39,142)=7.48, p=.000], as was the secondary MANOVA
[F(39,107)=3.735, p=.000]. As before, the resulting univariate ANOVAs from each
analysis are included in Table 5 below. Significant variables are denoted with an
asterisk.
Table 5: Experiment 5 Univariate ANOVAs by Behavior
Primary
Behavior
Eating
Gnawing*
Oral Behavior
Directed at Food*
Oral Behavior Not
Directed at Food*
Grooming*
Vocalizations
Boli (Tail Pinch)

Secondary

df
3
3
3

F
0.57
0.94
2.22

p
0.63
0.43
0.10

F
0.85
2.73
6.24

p
0.48
0.05
0.00

3

11.44

0.00

5.15

0.00

3
3
3

3.74
2.01
0.84

0.02
0.12
0.48

1.07
0.11
0.43

0.37
0.95
0.73

42

Table cont.
Line Crosses*
Rearing*
Head Shakes*
Body Shakes*
Boli (Open Field)
Freezing*

3
3
3
3
3
3

24.47
18.87
17.55
9.92
52.64
2.24

0.00
0.00
0.00
0.00
0.09
0.00

17.73
15.60
7.67
3.49
1.64
32.36

0.00
0.00
0.00
0.02
0.19
0.00

Experiment 5 Post Hoc Analysis. Primary post hoc analysis revealed that drug
conditions altered responding across seven behavioral variables: oral behavior without
food, grooming, line crosses, rearing, head shakes, body shakes, and freezing.
Secondary post hoc analysis revealed that drug conditions significantly altered
responding in eight behavioral variables: gnawing, oral behvaior directed at food, oral
behavior not directed at food, line crosses, rearing, head shakes, body shakes, and
freezing.
Gnawing (Figure 19). Secondary analysis showed that gnawing was reduced,
relative to saline, by spiperone + SDZ SER 082 (p=.038) and DOI + spiperone + SDZ
SER 082 (p=.047).
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Figure 19: Gnawing (Exp. 5 Secondary Analysis)
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Oral Behavior Directed at Food (Figure 20). Based on secondary analysis, oral
behavior directed at food was reduced, relative to controls, by DOI alone (p=.020), DOI
+ spiperone (p=.002), and DOI + spiperone + SDZ SER 082 (p=.004).
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Figure 20: OB w/ Food (Exp. 5 Secondary Analysis)
Oral Behavior Not Directed at Food (Figures 21 and 22). Both analyses generated
similar findings with respect to oral behavior not directed at food. OB w/o food was
reduced, relative to saline, by spiperone + SDZ SER 082 (pprimary=.000; psecondary=.016)
and DOI + spiperone + SDZ SER 082 (pprimary=.000; psecondary=.009). This behavior was
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Figure 21: OB w/o Food (Exp. 5 Primary Analysis)
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also significantly reduced, relative to DOI alone, by spiperone + SDZ SER 082 (pprimary=.007;
psecondary=.007), and DOI + spiperone + SDZ SER 082 (pprimary=.002; psecondary=.004).
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Figure 22: OB w/o Food (Exp. 5 Secondary Analysis)
Grooming (Figure 23). Primary analysis revealed that spiperone + SDZ SER 082
decreased grooming, relative to saline (p=.004), as did DOI + spiperone + SDZ SER 082
(p=.007).
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Figure 23: Grooming (Exp.5 Primary Analysis)
Line Crossing (Figures 24 and 25). Each analysis generated identical findings with
respect to line crossing. Line crossing was significantly reduced, relative to controls, by
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spiperone + SDZ SER 082 (pprimary=.000; psecondary=.000) and DOI + spiperone + SDZ
SER 082 (pprimary=.000; psecondary=.000). Line crossing was also significantly reduced,
relative to DOI alone, by spiperone + SDZ SER 082 (pprimary=.000; psecondary=.000) and
DOI + spiperone + SDZ SER 082 (pprimary=.000; psecondary=.000).
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Figure 24: Line Crosses (Exp. 5 Primary Analysis)
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Figure 25: Line Crosses (Exp. 5 Secondary Analysis)
Rearing (Figures 26 and 27). Both analyses indicated that rearing was reduced,
relative to saline, by DOI (pprimary=.000; psecondary=.000), spiperone + SDZ SER 082
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(pprimary=.000; psecondary=.000), and DOI + spiperone + SDZ SER 082 (pprimary=.000;
psecondary=.000).
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Figure 26: Rearing (Exp. 5 Primary Analysis)
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Figure 27: Rearing (Exp. 5 Secondary Analysis)
Head Shakes (Figures 28 and 29). Primary and secondary analyses revealed similar
results with respect to head shakes. Injections of DOI increased head shakes relative to
saline (pprimary/secondary=.000), spiperone + SDZ SER 082 (pprimary/secondary=.000), and DOI +
spiperone + SDZ SER 082 (pprimary/secondary=.000).
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Figure 28: Head Shakes (Exp. 5 Primary Analysis)
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Figure 29: Head Shakes (Exp. 5 Secondary Analysis)
Body Shakes (Figures 30 and 31). Once again, the primary and secondary analyses
yielded similar findings with respect to open field behavior. DOI increased body shakes
relative to saline (pprimary=.000; psecondary=.008), spiperone + SDZ SER 082 (pprimary=.000;
psecondary=.031), and DOI + spiperone + SDZ SER 082 (pprimary=.000; psecondary=.008). These
findings suggest that DOI-induced head and body shakes can be attenuated by a combination
of 5-HT2A/2C antagonists. However, based on data from the rotarod, tail pinch
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and other open field behaviors, it may simply be the case that the administration of multiple
antagonists resulted in sedation. This issue will be discussed in later sections.
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Figure 30: Body Shakes (Exp. 5 Primary Analysis)
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Figure 32: Body Shakes (Exp. 5 Secondary Analysis)
Freezing (Figures 33 and 34). Primary and secondary analyses produced similar
findings in the case of freezing behavior. Spiperone + SDZ SER 082 increased freezing
relative to saline (pprimary/secondary=.000) and DOI (pprimary/secondary=.000). DOI + spiperone +
SDZ SER 082 also increased freezing relative to saline (pprimary/secondary=.000) and DOI
(pprimary/secondary=.000).
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Figure 33: Freezing (Exp. 5 Primary Analysis)
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Figure 34: Freezing (Exp. 5 Secondary Analysis)
Rotarod Data. In all five experiments, ANOVAs for rotarod data failed to achieve
statistical significance. However, in Experiment 5, aberrations were seen in animals injected
with spiperone + SDZ SER 082, as well as DOI + spiperone + SDZ SER 082. In
both instances, animals’ time spent on the rotarod was decreased (nonsignificantly) relative
to DOI alone and controls. It is worthy of note that any deviation from normal rotarod
performance was exceedingly rare in this experiment. Additionally, animals in
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aforementioned groups exhibited behavior suggestive of sedation in both the tail pinch and
open field. These issues will be addressed in the following discussion.
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Discussion
The current study was conducted in an effort to further examine the influence of
serotonergic ligands on stress responding in rats. Eight hypotheses were tested over the
course of five experiments. The following discussion will examine each of the hypotheses
based on findings from the secondary analyses presented in the previous section.
Hypothesis 1: The Non-selective 5-HT2 Agonist, Injected Subcutaneously, Will
Decrease Tail Pinch-induced Stress Responding in Rats
Both the middle and high doses of DOI were shown to reduce tail pinch-induced oral
behavior directed at food (Exp. 1,4, and 5). This replicates the previously published finding
from our laboratory that DOI decreases stress-evoked oral behavior (Hawkins, et al., 2002).
The effects of DOI on oral behavior can be interpreted in various ways. The current paper
will examine the findings in the context of published work regarding the effects of DOI in
various models of stress and anxiety. The possibility that the behavioral effects of DOI are
the result of increased satiety, or of a nonspecific malaise, will also be examined.
DOI’s Effect on Stress Responding. Results of Experiment 1, 4, and 5 indicate that
DOI dose-dependently reduces stress-evoked oral behavior directed at food. This finding is
consistent with much of the existing literature regarding 5-HT2A/2C agonists and their effects
on stress and anxiety. Although these studies employ different models of stress, it is
possible to generalize the findings in terms of the general effects of 5-HT2A/2C agonists on
paradigm-specific behavior.
Peripheral injections of DOI have been shown to increase punished responding in the
four-plate test, a finding indicative of decreased sensitivity to physical stress (Dhonnchadha,
Hascoet, Jolliet, and Bourin, 2003). Central and peripheral administration of 5-HT2
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agonists have also been shown to decrease escape behavior in models involving aversive
stimuli, such as direct stimulation of the dorsal periaqueductal gray and exposure to the
elevated T-plus maze (de Paula Soares, 2004; Mora, Netto, and Graeff, 1997; Zangrossi,
et al., 2001; Graeff, et al., 1993). These findings, coupled with a replicated demonstration
that DOI reduces stress-evoked oral behavior in our laboratory, suggest that 5-HT2A/2C
agonists decrease behavioral responding to physical stress.
DOI and Satiety. It is possible that the effects of DOI are the result of an alteration in
behavioral satiety sequences in rodents. Although the present study did not compare eating
in tail pinch animals versus unstressed controls, other studies have demonstrated that tail
pinch stress increases ingestive behavior in rodents (Levine and Morley, 1981; Koch and
Bodnar, 1993; Szechtman and Hall, 1980; Heinrichs, et al., 1992). Stress-induced increases
in food intake are blockable with central and peripheral administration of DOI and other 5HT2A/2C agonists (Currie, Coiro, Niyomchai, Lira, and Farahmand, 2002; Currie, Saxena, and
Tu, 1999; Currie and Coscina, 1997). These behavioral effects have been attributed to the
ability of 5-HT2 agonists to activate the HPA axis, thereby slowing gastric emptying and
inducing satiety (Raghavendra and Kulkarni, 2000; Ferrari, Pelloni, and Guiliani, 1992;
Baker, Duggan, Barber, and Booth, 1998; Francis, Critchley, Dourish, and Cooper, 1995).
Although the current study consistently demonstrated that DOI reduces oral behavior
directed at food, there was no statistically significant DOI-induced reduction in eating or
gnawing. Thus, the suggestion that DOI induced satiety in the current study must be made
cautiously. We did observe a dose-dependent trend toward reduced eating following DOI
injections in Experiment 1. Low, medium, and high doses of DOI reduced eating, relative to
saline, by 10, 70, and 71%, respectively. Additionally, previous work in our lab has
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demonstrated that DOI dose-dependently reduces eating and gnawing (Hawkins, et al.,
2002).
Drug-induced Malaise. 5-HT and related compounds are known to induce malaise, a
behavioral profile typified by nausea, tremor, and fatigue (DeVry, Eckel, Kuhl, and
Schreiber, 2000). This is a potential confound when interpreting the effects of DOI on
ingestion and oral behavior, as the anorectic behavioral profile seen in these studies may
indicate nausea, rather than a decrease in anxiety (DeVry, et al., 2000). A study involving
the co-administration of DOI and an anti-emetic compound might be of utility in determining
if nausea is responsible for the behavioral effects produced by 5-HT2 agonists.
Hypothesis 2: The Effect of DOI On Tail Pinch-induced Stress Responding Will be
Reduced by Peripheral Co-administration of the Selective 5-HT2A Antagonist,
Spiperone
Experiment 4 examined the effects of co-administration of a single antagonist with DOI.
Spiperone did not alter the behavioral effects of DOI in the tail pinch condition. This
finding is inconsistent with previous reports that spiperone blocks DOI-induced hypophagia
in tail-pinched rats (Samarghandian, Ohata, Yamauchi, and Shibasaki, 2003). It should be
noted that the Samarghandian, et al. study employed intracerebroventricular injections of
spiperone. As such, it is possible that the permeability of the blood-brain to spiperone may
be a factor moderating the drug’s effects. Although spiperone is known to cross the BBB,
definitive data regarding the degree to which spiperone crosses this barrier are not currently
available (Herberg, and Wishart, 1980).
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Hypothesis 3: The Effect of DOI on Tail Pinch-induced Stress Responding Will be
Reduced by Peripheral Co-administration of the Selective 5-HT2C Antagonist, SDZ
SER 082
Experiment 4 failed to produce any evidence that SDZ SER 082 altered behavioral
responding to tail pinch and DOI injection. Although relatively few studies employing SDZ
SER 082 have been published, this finding is inconsistent with reports that SDZ SER 082
blocks 5-HT-induced behavior in certain models of stress (de Paula Soares and Zangrossi,
2004). Further evidence of SDZ SER 082’s ability to alter oral and ingestive behavior has
been demonstrated in studies involving 5-HT2-selective compounds (Castro, et al., 2003,
Castro, et al., 2002, Currie, Coiro, Nyomchai, Lira, and Farahmand, 2002 ). However, none
of these studies examined stress-evoked oral behavior, as was the case in the current study.
Additionally, these studies involved central, rather than peripheral, injections of 5-HT2
ligands. Thus, the possibility exists that the effects of SDZ SER 082 are limited by the
compound’s ability to cross the BBB. Still, SDZ SER 082 has been shown to alter
behavioral responding when administered peripherally (Goudie, Smith, Taylor, Taylor, and
Tricklebank, 1998; Mora, Netto, and Graeff, 1997). While 5-HT2C receptors are known to
exist in the periphery, it is more plausible that the effects of SDZ SER 082 on anxiety and
stress are centrally-mediated, suggesting permeability of the BBB to spiperone (Mora, Netto,
and Graeff, 1997). Conclusive data regarding the permeability of the BBB to SDZ SER 082
are not currently available, however.
Hypothesis 4: Spiperone and SDZ Will Have No Effect on Stress Responding When
Administered Alone
Experiments 2 and 3 examined the effects of spiperone and SDZ SER 082, injected
individually. Both primary and secondary MANOVAs were not significant, indicating that
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neither compound altered behavioral responding when injected alone. This is compatible
with previous findings that 5-HT2A antagonists are ineffective in altering anxious behavior
evoked by stressors (Gleeson, Ahlers, Mansbach, Foust, and Barrett, 1989; Griebel, Perrault,
and Sanger, 1997; Setem, Pinheiro, Motta, Morato, and Cruz, 1999, Bourin and Hascoet,
2003). Conversely, various studies have demonstrated that 5-HT2A and 5-HT2C antagonists,
injected alone, decrease stress responding in various rodent models (Stutzmann, et al., 1991,
Motta, Maisonnette, Morato, Castrechini, and Brandao, 1992, Costall and Naylor, 1995;
Mora, et al., 1997; Graeff, Netto, and Zangrossi, 1998; Gacsalyi, et al., 1997, Griebel, et al.,
1997; Dekeyne, Denorme, Monneyron, and Millan, 2000). However, findings that these
antagonists increase stress responding have been reported also (Olivier, et al., 1998, Setem,
et al., 1999, Maisonette, et al., 2000). The discrepancy in these findings may be partially
attributable to the nature of the stressor employed in these studies, an issue that has been
addressed in the Deakin and Graeff theory of 5-HT and anxiety (discussed below).
Hypothesis 5: Simultaneous Administration of Spiperone and SDZ SER 082 Will
Result in Greater Antagonism of DOI’s Effects Than That of Either Antagonist
Administered Alone
Experiment 5 examined the possibility that co-administration of spiperone and SDZ
SER 082 would alter DOI-induced behavioral responding in a manner distinguishable from
the effects produced by either antagonist alone. Spiperone + SDZ SER 082 decreased
behavioral responding across several variables in the tail pinch stressor condition and in the
open field: gnawing, oral behavior directed at food, oral behavior not directed at food, line
crossing, and rearing. Additionally, spiperone + SDZ SER 082 increased freezing behavior
in the open field. These effects were observed when these antagonists were injected
together, as well as when they were co-administered with DOI. All of these behavioral
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findings are indicative of decreased motor activity. Casual observation of these animals
during testing, coupled with the behavioral findings above, suggest a pharmacological, rather
than physiological effect of 5-HT2 antagonists on behavioral responding.
Antagonism of Head and Body Shakes. In addition to altering the behavioral
variables discussed in the previous section, injection of spiperone + SDZ SER 082 was
shown to abolish DOI-induced head shakes and body shakes. This finding is consistent with
previous reports from our laboratory and others that head and body shakes are mediated at
the level of the 5-HT2 receptor (Hawkins, et al., 2002; Marek, 2003; Mitchell, Fairhall,
Fretcher, and Redfern, 2003; Koskinen, Haapalinna, and Sirvio, 2003). Combined injections
of spiperone and SDZ SER 082 were equally as effective as SDZ SER 082, as they both
abolished head shakes. However, the same combination of antagonists abolished body
shakes, whereas individual antagonists were without effect. Thus, it would appear that
simultaneous administration of 5-HT2 antagonists was more effective than either antagonist
injected alone. This finding should be interpreted cautiously, as it is possible that the
pharmacological effects of multiple antagonists outweigh their apparent antagonistic effects.
Hypothesis 6: Subcutaneous Injection of DOI Will Have an Anxiolytic Effect on
Animal Behavior in the Open Field
DOI consistently reduced rearing, while increasing the number of head shakes, in the
open field. DOI also increased body shakes, relative to saline, in experiment 5.
Rearing. DOI’s effects on reducing rearing can be interpreted alternatively as a decrease
in exploratory behavior (anxiogenesis), a decrease in escape behavior (anxiolysis), or
general motor impairment. It seems unlikely that this effect on rearing is due to motor
impairment, as line crossing, freezing, and rotarod performance were unaffected by DOI.
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Thus, the third interpretation will not be addressed in the current discussion. A
preponderance of rodent studies classify reductions in rearing as an indication of
anxiogenesis (To and Bagdy, 1999; Rogers, et al., 2000; Singh, Jaiswal, Singh, and
Bhattacharya, 1998; Osborn, Yu, Gabriel, and Weinberg, 1998; Broderick, Hope, and
Jeannot, 1998; Cornwell-Jones, et al., 1992). In rare cases, reductions in “vigilant” rearing,
whereby an animal rears in response to a predator’s odor, have been reported as an anxiolytic
effect (Dielenberg and McGregor, 2001). Given the lack of evidence that DOI induces
motor impairment, it is concluded that DOI alters rearing in a manner consistent with an
anxiogenic behavioral profile. This finding stands in contrast to the hypothesis that DOI
would reduce stress responding to tail pinch, a discrepancy that may be accounted for by the
Deakin and Graeff theory of 5-HT and anxiety.
Dual-activation Theory of 5-HT. The Deakin and Graeff theory of 5-HT and anxiety
proposes that two serotonergic pathways selectively mediate distinct physiological responses
to distal and proximal threats. The former pathway is composed of the dorsal raphe nuclei,
which innervate areas of the amygdala and frontal cortex. Upon activation, this 5-HT
pathway is thought to produce anxiogenic behavior in response to distal threats. The latter
5-HT pathway, composed of the dorsal raphe and its connections to the periventricular and
periaqueductal gray matter, is thought to produce an anxiolytic response to unconditioned
proximal threats. Although the current study was not explicitly designed to distinguish
between proximal and distal threats, it is reasonable to conclude that tail pinch stress may be
classified as a stimulus that produces unconditioned fear by way of proximal threat. Similar
parallels can be drawn between the open field stressor and the distal threat of the Deakin and
Graeff theory, inasmuch as this model represents an unfamiliar, anxiety-provoking
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environment that is not characterized by an immediate physical threat to the animals involved.
The findings of the current study are consistent with the dual-activation theory in that
DOI was shown to reduce stress responding to a proximal threat (tail pinch) and increase
anxiogenic behavior in the open field. However, further examination of selective
serotonergic compounds in experimental models designed to accurately represent the
constructs of proximal and distal threat is warranted.
Head and Body Shakes. DOI consistently elevated the frequency of head and body
shakes when administered in medium and high doses. This effect has been observed in our
laboratory and others (Hawkins, et al., 2002; Marek, 2003; Mitchell, Fairhall, Fretcher, and
Redfern, 2003; Koskinen, Haapalinna, and Sirvio, 2003; Whitton, Sarna, Datla, and Curzon;
Wettstein, host, and Hitchcock, 1999) and is generally regarded as an effect of 5-HT2
agonists unrelated to stress.
Hypothesis 7: The Effect of DOI on Open Field Behavior Will be Reduced by
Spiperone, SDZ SER 082, or a Combination of the Two Antagonists
Experiments 4 and 5 examined the effects of 5-HT2 antagonists on DOI-induced
behavior.
Single Antagonist (Experiment 4). Others have concluded that DOI’s effect on
inducing head shakes is due to activation of the 5-HT2A receptor (Mitchell, et al., 2003;
Islam, Thompson, Akhtar, and Handley, 2004; Marek, 2003; Izumi, et al., 2002; Kulikov, et
al., 1997, Gauffre, Aguerre, Mormede, and Chaouloff, 1997, Dursun and Handley, 1996).
Additional support for the role of the 5-HT2A receptor in mediating head shakes has come
from studies of genetically-altered rats. Central glucocorticoid receptor “knockdown” rats,
altered to express only 20% of normal glucocorticoid receptors, demonstrate elevated levels
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of 5-HT2A protein mRNA in the hypothalamus and frontal cortex, as well as hypersensitivity
to DOI-induced head shakes (Islam, et al., 2004). The implications of this study are twofold:
5-HT2A receptors are largely responsible for mediating head shakes, and that glucocorticoid
receptors may regulate 5-HT2A receptor expression. In Experiment 4 of the present study,
however, the 5-HT2A antagonist spiperone did not block DOI-induced head shaking, while
the 5-HT2C antagonist SDZ SER 082 completely abolished it. As such, the current study
indicates that the 5-HT2C receptor may also play a role in mediating head shaking in rodents.
Multiple Antagonists (Experiment 5). Combined injections of spiperone + SDZ SER
082 were shown to abolish DOI-induced head shakes and body shakes in Experiment 5. This
finding is consistent with reports that ketanserin, a 5-HT2A/2C antagonist, reverses DOIinduced head and body shakes (Dursun and Handley, 1996; Fone, Robinson, and Marsden,
1991) Administration of spiperone + SDZ SER 082, as well as DOI + spiperone + SDZ SER
082 also resulted in decreased line crossing and rearing and increased freezing time in the
open field. Informal observation of these animals, coupled with analyses of the
aforementioned behaviors suggests a pharmacological effect of multiple antagonists, rather
than a specific ability of these compounds to mediate stress-related behavior.
Hypothesis 8: The Administration of DOI, Spiperone, SDZ SER 082 and
Combinations Thereof, Will Not Impair General Motor Function, as Measured by
Rotarod Performance and Ambulation in the Open Field
No combination of drugs was found to alter rotarod performance significantly. However,
co-administration of SDZ SER 082 and spiperone, as well as the co-administration of DOI,
spiperone, and SDZ SER 082 seemed to produce motoric impairment. Although the
statistical analysis of rotarod data from these groups was not significant, there was a trend
toward reduced rotarod time for animals in each of the aforementioned drug conditions. In
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Experiment 5, the respective means for saline, OI 0.5, spiperone + SDZ SER 082, and DOI +
spiperone + SDZ SER 082 were as follows: 29, 29, 20, and 17 of a possible 30 seconds. As
mentioned previously, any deficits in rotarod performance were rare in these experiments.
The largest deviation from the rotarod time criterion in Experiments 1-4 was approximately
5%, contrasted with the 34% and 44% deficits in total rotarod time observed after
administration of spiperone + SDZ SER 082 and DOI + spiperone + SDZ SER 082 in
Experiment 5.
In the open field also, the co-administration of SDZ SER 082 and spiperone, as well as
the co-administration of DOI, spiperone, and SDZ SER 082, seemed to impair motor
activity, as indicated by increased freeze time and decreases in rearing and line crossing.
These behavioral effects are suggestive of overdose.
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Conclusion
The most consistent findings of the current study are that DOI attenuates rearing and
oral behavior directed at food, while increasing the frequency of head and body shakes in the
open field. DOI’s dose-dependent effects on tail pinch-induced oral behavior indicate that
this compound has the potential to reduce responding to proximal threats. Conversely,
DOI’s effects in the open field suggest an anxiogenic response to a novel, threatening
environment. The observation that DOI produced opposing effects in separate behavioral
models may be accounted for by the 5-HT dual-activation theory, discussed previously
(Graeff, et al., 1996).
Administration of spiperone, SDZ SER 082, or a combination of the two drugs, did not
block the effects of DOI on oral behavior or rearing. While DOI-induced head shaking was
antagonized by co-administration of the 5-HT2C antagonist, SDZ SER 082, as well as by a
combination of SDZ SER 082 and spiperone, it is concluded that neither antagonist was able
to alter stress-related behavior induced by the administration of DOI.
Future research should be directed at elucidating the brain areas or peripheral structures
that mediate relevant stress-induced behavior. It may be necessary to selectively target brain
areas of interest (such as the PVN), as blood-brain permeability remains a potential
confound in studies involving peripheral injection of drugs. Additionally, the development of
agonists selective for the various 5-HT2 receptor subtypes which readily cross the BBB may
prove beneficial in related behavioral research.
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